CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

EFFECTOR 37.5 - The Insidious Effort to Privatize Public Airwaves Since 1990 EFF has published EFFector to help keep readers on the bleeding edge of their digital rights. We know that the intersection ...

A newly identified rare cell subset that drives immune tolerance in dietary and gut microbiota may offer a new therapeutic ...

Kairos Pharma (NYSE American: KAPA) presented new preclinical data at the ASCO 2025 Annual Meeting on its investigational small molecule GITR ligand ...

The investment comes off the back of the Strategic Defence Review, which recommends that the department use more autonomy.

Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

Abstract: A 3-DOF force-controlled end-effector based on a parallel mechanism is an effective approach for high-precision polishing in industrial applications. However, the dynamic modeling of ...

EVANDALE, Ohio—Engine makers GE Aerospace and Kratos Turbine Technologies expanded a partnership on small affordable turbofan ...

This article reports the design, synthesis, and evaluation of a novel class of molecules of intermediate size (approximately 7000 Da), which possess both the targeting and effector functions of ...